High-Multiplex Semiconductor Device To Detect, Quantify And Genotype Infectious Agents
Santa Clara Convention Center, CA, USA
Grand Ballroom G
12:00 - 12:20
The emergence of infectious agents that are progressively resistant to available antibiotics is a growing, worldwide health crisis that threatens a return to the pre-antibiotic era. Amongst the proposed solutions to this global problem is a call for the creation and deployment of a new generation of molecular diagnostics that rapidly, and at the point-of-care, identify pathogens in a clinical sample and comprehensively scan their genomes for mutations that confer drug resistance. In this talk we will describe a fully-integrated opto-electronic biosensor array (biochip) fabricated by a complementary metal oxide semi-conductor (CMOS) process and paired with a novel nucleic acid detection chemistry that enables on-chip nucleic acid amplification, microbial load quantification, mutation detection and parallel solid-phase melt curve analysis of up to 1000 sequences. We demonstrate the versatility and potential of this platform by detecting and quantifying multiple DNA and RNA respiratory viruses in a sample and identifying, simultaneously and in parallel, >50 drug resistance mutations located in six genes of Mycobacterium tuberculosis.
Arjang Hassibi is the President, Chief Executive Officer, and a board member of InSilixa. He founded InSilixa in 2012 to commercialize the proprietary CMOS biosensor technologies that he had been developing in academia for almost a decade.
Dr. Hassibi's area of expertise is the intersection of biotechnology and engineering, specifically biosensors and bioelectronics, integrated array technologies, and DNA sequencing. Prior to starting InSilixa, he was a faculty member at the Electrical and Computer Engineering Department and the Institute for Cellular and Molecular Biology of The University of Texas at Austin. During his career, he has held various R&D positions in both industry and academia including Stanford Genome Technology Center, IBM Research at Yorktown, California Institute of Technology (Caltech), and Xagros Genomics, a startup company which he co-founded in 2001. Most recently, he was the Healthcare Thrust Lead at the Silicon Research Corporation (SRC), the world's leading semiconductor technology research consortium.
Dr. Hassibi received his B.Sc. with the highest honors from the University of Tehran, Iran, and both his M.Sc. and Ph.D. degrees from Stanford University, all in electrical engineering. He attended Caltech for his postdoctoral training. Dr. Hassibi has more than 100 technical publications and patents, almost all in the multidisciplinary area of biosensors and bioelectronics.
InSilixa, Inc., headquartered in Sunnyvale, CA, is a multidisciplinary, highly motivated and highly technical team comprised of industry veterans with diverse backgrounds in semiconductors, biotechnology, medicine, and informatics. Founded in 2012, InSilixa is driven by the quest to democratize and drive down the cost of molecular diagnostics worldwide by leveraging its proprietary semiconductor-based CMOS biochip technology. To that end, the company is developing point-of-care (PoC) and near patient platforms for the delivery of low cost, high-performance, and mass-deployable solutions for DNA and protein-based diagnostic testing.